Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Expenses (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Operating Expenses for 4 consecutive years, with $81.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 14.14% to $81.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $285.9 million, a 17.94% decrease, with the full-year FY2025 number at $285.9 million, down 17.94% from a year prior.
  • Operating Expenses was $81.2 million for Q4 2025 at Day One Biopharmaceuticals, up from $64.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $123.0 million in Q2 2024 to a low of $27.7 million in Q1 2022.
  • A 4-year average of $61.7 million and a median of $61.8 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 149.72% in 2024, then plummeted 44.0% in 2025.
  • Day One Biopharmaceuticals' Operating Expenses stood at $42.7 million in 2022, then surged by 39.24% to $59.5 million in 2023, then soared by 58.85% to $94.5 million in 2024, then dropped by 14.14% to $81.2 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Operating Expenses are $81.2 million (Q4 2025), $64.0 million (Q3 2025), and $68.9 million (Q2 2025).